[{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"HBM9161","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Receives FDA IND Approval for Phase 2 Clinical Trial and Orphan Drug Designation for Anti-PD-L1 mAB","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"HBM9167","moa":"PD-L1","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mount Sinai Health System","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mount Sinai and Harbour BioMed Collaborate to Advance Novel Biotherapies for the Treatment of Cancer and Coronavirus COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Mount Sinai Health System","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Mount Sinai Health System"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"SK Holdings","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Raises $75 Million Series B+ Venture Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"HBM4003","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0.080000000000000002,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Nona Biosciences \/ SK Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ SK Holdings"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Clinical Trial of HBM916","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces First Patient Dosed in Phase 1b\/2a Study of Anti-FcRn Batoclimab to Treat Neuromyelitis Optica Spectrum Disorder","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Join Hands to Develop Antibody Therapy to Prevent and Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Monoclonal Antibody","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ AbbVie","highestDevelopmentStatusID":"1","companyTruncated":"Nona Biosciences \/ AbbVie"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Receives Chinese Regulatory Approval to Begin Seamless Phase 2\/3 Clinical Trial of HBM9161 in Graves\u2019 Ophthalmopathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Hudson Bay Capital","pharmaFlowCategory":"D","amount":"$102.8 million","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation Biologics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Series C Financing","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Hudson Bay Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Hudson Bay Capital"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Collaborates with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"August 2020","year":"2020","type":"Collaboration","leadProduct":"Antibodies","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Vir Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Vir Biotechnology"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Gets Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HBM4003","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Doses First Patients in Two Phase II Clinical Studies of Batoclimab to Treat Myasthenia Gravis and Immune Thrombocytopenia","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept in Patients with Moderate-to-Severe Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tanfanercept","moa":"TNF alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"ABBV-47D11","moa":"SARS-CoV-2 spike protein","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Nona Biosciences \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ AbbVie"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BlackRock Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ BlackRock Fund","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ BlackRock Fund"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed's Batoclimab Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"HBM4003","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Gets IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"$25.0 million","newsHeadline":"Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"HBM7022","moa":"CLDN18.2\/CD3","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0.34999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.34999999999999998,"dosageForm":"","sponsorNew":"Nona Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"HBM4003","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"HBM7008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Porustobart","moa":"CTLA-4","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"CSPC Pharmaceutical Group","pharmaFlowCategory":"D","amount":"$138.6 million","upfrontCash":"$20.8 million","newsHeadline":"HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Agreement","leadProduct":"Batoclimab","moa":"FcRn","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0.14000000000000001,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Nona Biosciences \/ CSPC NBP Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ CSPC NBP Pharmaceutical"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"HBM7008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harbour BioMed Enters into a License and Collaboration Agreement with Moderna","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"mRNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Moderna","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Moderna"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Dragonfly Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Enters Agreement with Dragonfly Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Dragonfly Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Dragonfly Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 Antibody by the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"HBM1020","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mythic Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Mythic Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Mythic Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","amount":"$588.0 million","upfrontCash":"$25.0 million","newsHeadline":"Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Licensing Agreement","leadProduct":"HBM7008","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0.58999999999999997,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.58999999999999997,"dosageForm":"Injectable\/Injection","sponsorNew":"Nona Biosciences \/ Cullinan Oncology, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Cullinan Oncology, LLC"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Hanall Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Batoclimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nona Biosciences \/ Harbour BioMed","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosciences \/ Harbour BioMed"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Strategic Collaboration Agreement with PharmaEssentia Innovation Research Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ PharmaEssentia","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ PharmaEssentia"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"HBM1020","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Harbour BioMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harbour BioMed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Harbour BioMed \/ Not Applicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Batoclimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Harbour BioMed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Not Applicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"HBM9033","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Harbour BioMed","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harbour BioMed \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Harbour BioMed \/ Not Applicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ BeiGene","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ BeiGene"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Ingenia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ INGENIA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ INGENIA Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Bioconjugate","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Nona Biosciences"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Lycia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Lycia Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Lycia Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Evive Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Nona Biosciences"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,103.0 million","upfrontCash":"$53.0 million","newsHeadline":"Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"HBM9033","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nona Biosciences","amount2":1.1000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"5","companyTruncated":"Nona Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Boostimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Boostimmune","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Boostimmune"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$604.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Monoclonal Antibody-based Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0.59999999999999998,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.59999999999999998,"dosageForm":"","sponsorNew":"Nona Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Resubmits Batoclimab BLA to NMPA for Myasthenia Gravis Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Batoclimab","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III","graph3":"Harbour BioMed","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harbour BioMed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Harbour BioMed \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Harbour BioMed
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
